PPD

NOVEMBER 9, 2023

However, over the past decade, a trend toward incorporating multiple study populations into one protocol has slowly gathered momentum among drug developers. Improved prioritization Promising pipeline candidates with a strong early development protocol may see a positive impact to the net present value of an early-stage asset.

Clinical Development 52

Clinical Development Drug Development Clinical Research Treatment 52

PPD

NOVEMBER 21, 2023

The drug development industry is constantly adapting and evolving to bring novel therapeutics to market to improve the lives of patients across the globe. While the drug development industry experienced setbacks during the COVID-19 pandemic, the field  is again gaining momentum reminiscent of its pre-pandemic pace.

Clinical Development 52

Clinical Development Clinical Trials Trials Clinical Research 52

The Premier Consulting Blog

JULY 31, 2024

In this blog, we explain the role of clinical pharmacology in drug development and demonstrate how the right strategy can accelerate development under the US Food and Drug Administration (FDA) 505(b)(1) and 505(b)(2) New Drug Application (NDA) pathways.

Clinical Pharmacology 52

Clinical Pharmacology Drug Development Pharmacokinetics Drugs 52

Alta Sciences

NOVEMBER 15, 2024

4 Essential Topics to Cover in Your First CRO Meeting pmjackson Fri, 11/15/2024 - 19:22 Starting a partnership with a contract research organization (CRO) is a sometimes intimidating—yet exciting—first step in your drug development journey. Be prepared to share necessary information about your study with the CRO,” says Chad.

Drug Development 52

Drug Development Clinical Trials Trials Drugs 52

The Premier Consulting Blog

JUNE 18, 2023

This has opened new opportunities in pharmaceutical drug development, such as the ability to evaluate large complex databases and to integrate information in useful ways. One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

The Pharma Data

JULY 8, 2021

The update clarifies the indication by emphasizing information about the disease stages studied in the ADUHELM clinical trials. Information about the population studied has been previously communicated by Biogen and Eisai, including in the companies’ statement of June 23, 2021. Please see the full Prescribing Information.

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52

Drug Target Review

SEPTEMBER 5, 2024

However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company. See more information about Kristina here: [link]

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

Advarra

AUGUST 10, 2023

Given the relatively small populations affected by any one rare disease or condition, a pharmaceutical company developing an orphan drug may reasonably expect the final approved drug to generate relatively small sales (when compared with the drug development costs) and consequently incur a financial loss.

Drug Development 52

Drug Development Disease Therapies Engineering 52

Conversations in Drug Development Trends

AUGUST 23, 2023

Patients are the backbone of clinical trials, playing an essential role in the drug development process. This engagement is often less understood and is underutilized by sponsors, meaning a significant element of the trial and drug experience is missed during sponsor engagement with the FDA. Our mission is a lofty one.

FDA 96

FDA Trials Clinical Trials Disease 96

PPD

OCTOBER 16, 2023

Consent development: Informed consent is the most important step in the tokenization process. This enables deeper and more meaningful real-world insights on clinical study data. Tokenization can accelerate innovation in clinical trials and drug development.

Clinical Trials 98

Clinical Trials Trials Research Therapies 98

Alta Sciences

JULY 22, 2024

Recently, we have seen increasing numbers of complex FIH studies in CNS-active drugs to gather comprehensive data with a wider range of doses as early as possible. jpg Tags Clinical Trials Weight 1

Trials 52

Trials Clinical Trials Clinical Development Clinical Research 52

PPD

JULY 18, 2023

Nearly two-thirds of drug developers’ outsourcing budgets are now allocated to functional service provider (FSP) models or FSP hybrid models, according to research conducted by the PPD clinical research business of Thermo Fisher Scientific. Regular review and management of KPIs and budget. Escalations and risk mitigation.

Clinical Development 52

Clinical Development Drug Development International Clinical Research 52

NIH Director's Blog: Drug Development

SEPTEMBER 26, 2019

For those drug candidates that are ultimately doomed, “failing early” is key to reducing drug development costs. The ultimate goal is to accelerate the translation of basic discoveries into clinical breakthroughs. For more information about tissue chips, take a look at NIH’s Tissue Chip for Drug Screening program.

Drugs 72

Drugs Science Treatment Clinical Trials 72

Conversations in Drug Development Trends

MAY 14, 2024

As the strategists for Worldwide Clinical Trials’ rare disease sponsors, we design customized solutions that make a difference in achieving successful outcomes. Our approach is informed by our combined 30+ years in rare disease clinical development and our time in various stakeholder roles, such as scientists, CRAs, and project managers.

Disease 81

Disease Clinical Trials Trials Pharmaceutical Companies 81

Drug Target Review

MAY 7, 2024

How do AI-enhanced approaches accelerate the drug development process for rare diseases? AI holds the potential to revolutionise different aspects of healthcare, particularly in the realm of clinical trials.

Disease 59

Disease Clinical Trials Clinical Pharmacology Trials 59

The Pharma Data

DECEMBER 10, 2020

executive vice president of research and development. “We We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible.”. For additional information, please visit www.lexpharma.com. Safe Harbor Statement.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

FDA Law Blog: Drug Discovery

MARCH 7, 2024

Moreover, DMCs are being used in trials of modest size and in the context of increased globalization of medical product development. FDA notes that the distinctions between responsibilities for these groups and DMCs should be clearly defined, particularly with respect to access to unblinded information.

Clinical Trials 105

Clinical Trials Trials FDA Regulations 105

Alta Sciences

FEBRUARY 8, 2024

The FDA guidance, Evaluating Drug Effects on the Ability to Operate a Motor Vehicle , indicates that testing in early-phase clinical development should emphasize sensitivity over specificity in CNS effects. View the Driving Simulation Fact Sheet for more information.

Clinical Trials 52

Clinical Trials Trials Clinical Pharmacology Clinical Development 52

FDA Law Blog: Drug Discovery

JANUARY 4, 2023

The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. Other Questions. The Agency recommended that sponsors follow the requirements under 21 CFR 211.84(d)(2)

Therapies 59

Therapies Engineering Production FDA 59

The Pharma Data

DECEMBER 28, 2020

Dr Reimer will replace Dr Charlotte Russel and be overall medically responsible for Alligator’s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies. The information was submitted for publication, through the agency of the contact person set out above, at 9:00 a.m.

Clinical Development 40

Clinical Development Doctors Drug Development International 40

Drug Target Review

SEPTEMBER 10, 2024

The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. Hence, in many cases an earlier IND may be prevented by the timely provision of representative Drug Substance (DS) to execute such toxicology studies.

Drug Development 64

Drug Development Clinical Supply Production FDA 64

Vial

APRIL 10, 2024

The increasing costs associated with in-house drug development have prompted biotech and pharmaceutical companies to increasingly outsource to contract research organization s (CROs) for assistance. IQVIA has a vast collection of healthcare information, including over 1.2 increase on a reported basis and an 4.8%

Clinical Trials 52

Clinical Trials Trials Clinical Research Compliance 52

Drug Target Review

MAY 1, 2024

The advent of monoclonal antibodies paired with improvements in each ADC design component has led to the approval of 11 ADCs with more than 180 ADCs currently in clinical development. Jamie Rich, PhD is Senior Director of Technology, ADC Therapeutic Development at Zymeworks Inc.

Drugs 69

Drugs FDA Approval Organic Chemistry Small Molecule 69

PPD

NOVEMBER 14, 2023

In this complex environment, functional service partnership (FSP) models have become a solution of choice for pharmaceutical and biotech companies navigating the challenges of clinical development. This comes as the demand for qualified clinical research associates (CRAs) is expected to increase by more than 36% in the next decade.

Clinical Research 52

Clinical Research Clinical Development International Engineering 52

FDA Law Blog: Drug Discovery

OCTOBER 2, 2023

Two weeks ago, FDA published a draft of its latest drug development guidance explaining how drug and biological product developers can use this pathway to meet the statutory standard for efficacy. In the December 2019 Guidance, FDA writes that the clinical context for a disease (i.e.,

FDA 64

FDA Drug Development Disease Trials 64

The Pharma Data

OCTOBER 25, 2020

We are advancing the clinical development of mRNA-1273 with our Phase 3 COVE study, which is now fully enrolled with a representative demography of participants across ages, ethnicities and high-risk populations. For more information about the COVE study, click here. About Moderna.

Vaccine 52

Vaccine Clinical Development RNA Clinical Trials 52

The Premier Consulting Blog

JULY 9, 2023

These ICH guidance documents apply at different stages of development and address specific concerns regarding certain types of impurities or degradants. Impurities in new drug substances and new drug products ICH Q3A(R2) addresses impurities in the drug substance, and ICH Q3B(R2) addresses degradants in the drug product.

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52

PPD

DECEMBER 5, 2023

Non-footprint countries are regions where drug developers lack a physical presence, often in emerging markets or remote areas. These countries offer new opportunities for drug developers to access additional resources, ensure project continuity and rely on localized expertise for recruitment, regulatory insights and more.

Clinical Development 52

Clinical Development Clinical Research Drug Development International 52

The Connected Lab

APRIL 8, 2020

How is AI being applied in Drug Discovery efforts? It is reported that every one of the major pharmaceutical companies has announced a partnership with at least one AI-based drug development company, but how is AI being used to facilitate drug development? A Tough Road: Cost To Develop One New Drug Is $2.6

Pharma Companies 52

Pharma Companies Laboratories Drugs FDA Approval 52

PPD

MAY 11, 2023

The global COVID-19 pandemic increased awareness of the importance of vaccine development — both for drug developers and the public. The speed at which COVID-19 vaccines were developed was remarkable, but like most newly developed vaccines, there was variation among who could receive the shots and when.

Vaccine 52

Vaccine Clinical Trials Long-Term Care Facilities Trials 52

Drug Target Review

JULY 26, 2024

We have a dual aim: to use the power of sequencing for more personalised patient care; and to be able to leverage those datasets to progress various programmes within drug discovery. It also produces a dataset that is incredibly interesting for drug discovery. This helps produce a dataset that does lots of different things.

Clinical Trials 72

Clinical Trials Science Trials International 72

The Pharma Data

MARCH 28, 2022

These drug development programs include our acceleration of priority asset amlitelimab, an anti-OX40L antibody that aims to restore immune homeostasis between pro-inflammatory and anti-inflammatory T cells. For background slides and webcast information, please refer to the following link. CEST / 8 a.m. CEST / 7 a.m.

Small Molecule 52

Small Molecule Clinical Development Disease Science 52

Drug Target Review

JANUARY 15, 2024

CD8+ T cells are a type of lymphocyte that specialises in scanning information presented by HLA Class I. 3 Conclusion Human evolution has developed an elegant system that allows HLA presentation to open a ‘window into the cell’ and enable very precise immune monitoring of cellular health and disease states.

Engineering 110

Engineering DNA Virus Immune Response 110

Drug Target Review

DECEMBER 13, 2024

7,8 The discovery of these biomarkers provides valuable insights into prognosis and disease progression, while also guiding the clinical development of new targeted immunotherapies. Antibody-drug conjugates: Principles and opportunities. Phuna ZX, Kumar PA, Haroun E, Dutta D, Lim SH. 2024;347:122676. BMC Cancer. 2024;24(1):898.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

The Pharma Data

OCTOBER 18, 2020

DUBLIN–( BUSINESS WIRE )– Inflection Biosciences Ltd , a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of industry veteran Gregory I. Greg possesses a wealth of experience in developing new cancer therapeutics across multiple U.S. Berk, MD, to its Board of Directors.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

SEPTEMBER 15, 2020

Join best-in-class experts from S-Clinica to discuss how IRT and supply forecasting grants sponsors the flexibility to utilize information consistently and accurately, while helping to reduce supply drug waste and efficiently manage study and potential and existing inventory changes.

Clinical Supply 52

Clinical Supply Clinical Trials Doctors Clinical Development 52

The Pharma Data

JANUARY 7, 2021

Cerecor intends to use the net proceeds of the offering for general corporate purposes and working capital, primarily to support the ongoing clinical development of key assets within its pipeline and for general and administrative expenses. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007.

Clinical Development 52

Clinical Development Disease Treatment FDA Approval 52